Cancer Res Treat.  2017 Oct;49(4):937-946. 10.4143/crt.2016.423.

Efficacy and Safety of First-Line Necitumumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in East Asian Patients with Stage IV Squamous Non-small Cell Lung Cancer: A Subgroup Analysis of the Phase 3, Open-Label, Randomized SQUIRE Study

Affiliations
  • 1Division of Hematology/Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. kpark@skku.edu
  • 2Department of Medicine, Gachon University Gil Medical Center, Incheon, Korea.
  • 3Saint Luke's Medical Center, Quezon City, Philippines.
  • 4Chief Division of Medical Oncology, Department of Medicine, Faculty of Medicine, Maharaj Nakorn Chiang Mai, Chiang Mai University, Chiang Mai, Thailand.
  • 5Department of Internal Medicine, Chonbuk National University Hospital, Jeonju, Korea.
  • 6Lilly Deutschland GmbH, Bad Homburg, Germany.
  • 7Eli Lilly and Company, Gurgaon, India.
  • 8Eli Lilly Interamerica Inc., Buenos Aires, Argentina.

Abstract

PURPOSE
The phase 3 randomized SQUIRE study revealed significantly longer overall survival (OS) and progression-free survival (PFS) for necitumumab plus gemcitabine and cisplatin (neci+GC) than for gemcitabine and cisplatin alone (GC) in 1,093 patients with previously untreated advanced squamous non-small cell lung cancer (NSCLC). This post hoc subgroup analysis assessed the efficacy and safety of neci+GC among East Asian (EA) patients enrolled in the study.
MATERIALS AND METHODS
All patients received up to six 3-week cycles of gemcitabine (days 1 and 8, 1,250 mg/m²) and cisplatin (day 1, 75 mg/m²). Patients in the neci+GC arm also received necitumumab (days 1 and 8, 800 mg) until disease progression or unacceptable toxicity. Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated from stratified Cox proportional hazards models.
RESULTS
In EA patients, there were improvements for neci+GC (n=43) versus GC (n=41) in OS (HR, 0.805; 95% CI, 0.484 to 1.341) and PFS (HR, 0.720; 95% CI, 0.439 to 1.180), consistent with the results for non-EA patients observed in the present study. The overall safety data were consistent between EA and non-EA patients. A numerically higher proportion of patients experienced serious adverse events (AEs), grade ≥ 3 AEs, and AEs with an outcome of death for neci+GC versus GC in EA patients and EA patients versus non-EA patients for neci+GC.
CONCLUSION
Although limited by the small sample size and post hoc nature of the analysis, these findings are consistent with those of the overall study and suggest that neci+GC offers a survival advantage and favorable benefit/risk for EA patients with advanced squamous NSCLC.

Keyword

Non-small-cell lung carcinoma; Cisplatin; East Asian; Gemcitabine; Necitumumab; Epidermal growth factor receptor

MeSH Terms

Arm
Asian Continental Ancestry Group*
Carcinoma, Non-Small-Cell Lung*
Cisplatin*
Disease Progression
Disease-Free Survival
Humans
Proportional Hazards Models
Receptor, Epidermal Growth Factor
Sample Size
Cisplatin
Receptor, Epidermal Growth Factor

Figure

  • Fig. 1. Patient flow for EA patients enrolled in the SQUIRE study. Note that patients in the neci+GC arm who had not progressed at the end of the induction phase could continue to receive single-agent necitumumab in the continuation phase until radiographic documentation of disease progression, unacceptable toxicity, or withdrawal of consent. EA, East Asian; neci+GC, necitumumab plus gemcitabine and cisplatin; GC, gemcitabine and cisplatin; ITT, intent-to-treat.

  • Fig. 2. Kaplan-Meier analysis of overall survival and progression-free survival in the EA and non-EA subpopulations. Overall survival in the neci+GC and GC arms in the EA subpopulation (A) and non-EA subpopulation (B). Progression-free survival in the neci+GC and GC arms in the EA subpopulation (C) and non-EA subpopulation (D). EA, East Asian; neci+GC, necitumumab plus gemcitabine and cisplatin; GC, gemcitabine and cisplatin; HR, hazard ratio; CI, confidence interval.


Reference

References

1. Perez-Moreno P, Brambilla E, Thomas R, Soria JC. Squamous cell carcinoma of the lung: molecular subtypes and therapeutic opportunities. Clin Cancer Res. 2012; 18:2443–51.
Article
2. Gandara DR, Hammerman PS, Sos ML, Lara PN Jr, Hirsch FR. Squamous cell lung cancer: from tumor genomics to cancer therapeutics. Clin Cancer Res. 2015; 21:2236–43.
Article
3. Gentzler RD, Johnson ML. Complex decisions for first-line and maintenance treatment of advanced wild-type non-small cell lung cancer. Oncologist. 2015; 20:299–306.
Article
4. Pirker R, Pereira JR, Szczesna A, von Pawel J, Krzakowski M, Ramlau R, et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an openlabel randomised phase III trial. Lancet. 2009; 373:1525–31.
Article
5. Sgambato A, Casaluce F, Maione P, Rossi A, Ciardiello F, Gridelli C. Cetuximab in advanced non-small cell lung cancer (NSCLC): the showdown? J Thorac Dis. 2014; 6:578–80.
6. Hirsch FR, Varella-Garcia M, Bunn PA Jr, Di Maria MV, Veve R, Bremmes RM, et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol. 2003; 21:3798–807.
Article
7. Dacic S, Flanagan M, Cieply K, Ramalingam S, Luketich J, Belani C, et al. Significance of EGFR protein expression and gene amplification in non-small cell lung carcinoma. Am J Clin Pathol. 2006; 125:860–5.
Article
8. Greillier L, Tomasini P, Barlesi F. Necitumumab for non-small cell lung cancer. Expert Opin Biol Ther. 2015; 15:1231–9.
Article
9. Thatcher N, Hirsch FR, Luft AV, Szczesna A, Ciuleanu TE, Dediu M, et al. Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial. Lancet Oncol. 2015; 16:763–74.
Article
10. Sekine I, Yamamoto N, Nishio K, Saijo N. Emerging ethnic differences in lung cancer therapy. Br J Cancer. 2008; 99:1757–62.
Article
11. Iwasaki M, Hinotsu S, Katsura J. Clinical trials and approval of anti-cancer agents. Jpn J Clin Oncol. 2010; 40 Suppl 1:i65–9.
Article
12. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004; 304:1497–500.
13. Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, Wistuba II, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst. 2005; 97:339–46.
Article
14. O’Donnell PH, Dolan ME. Cancer pharmacoethnicity: ethnic differences in susceptibility to the effects of chemotherapy. Clin Cancer Res. 2009; 15:4806–14.
Article
15. Edge S, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC cancer staging manual. 7th ed. New York: Springer;2010.
16. Pirker R, Pereira JR, von Pawel J, Krzakowski M, Ramlau R, Park K, et al. EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study. Lancet Oncol. 2012; 13:33–42.
Article
17. Segaert S, Van Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol. 2005; 16:1425–33.
Article
18. Chen P, Wang L, Li H, Liu B, Zou Z. Incidence and risk of hypomagnesemia in advanced cancer patients treated with cetuximab: a meta-analysis. Oncol Lett. 2013; 5:1915–20.
Article
19. Petrelli F, Cabiddu M, Borgonovo K, Barni S. Risk of venous and arterial thromboembolic events associated with anti-EGFR agents: a meta-analysis of randomized clinical trials. Ann Oncol. 2012; 23:1672–9.
Article
20. Socinski MA, Bondarenko I, Karaseva NA, Makhson AM, Vynnychenko I, Okamoto I, et al. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial. J Clin Oncol. 2012; 30:2055–62.
Article
21. Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, Poddubskaya E, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015; 373:123–35.
Article
22. Li S, Kussie P, Ferguson KM. Structural basis for EGF receptor inhibition by the therapeutic antibody IMC-11F8. Structure. 2008; 16:216–27.
Article
23. Pujol JL, Pirker R, Lynch TJ, Butts CA, Rosell R, Shepherd FA, et al. Meta-analysis of individual patient data from randomized trials of chemotherapy plus cetuximab as first-line treatment for advanced non-small cell lung cancer. Lung Cancer. 2014; 83:211–8.
Article
Full Text Links
  • CRT
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr